Information Provided By: 
Fly News Breaks for February 24, 2017
SPLK
Feb 24, 2017 | 08:31 EDT
JPMorgan analyst Mark Murphy says that while Splunk's billings in Q4 grew a "respectable" 35% year-over-year, beating the consensus of 29%, the quarter marked the slowest billings growth rate in over three years. The analyst admits the company has a "sound position as a leader in machine data," but keeps a Neutral rating on the shares due to valuation. Murphy maintains a $62 price target on Splunk.
News For SPLK From the Last 2 Days
SPLK
Apr 23, 2024 | 08:31 EDT
New option listings for April 23rd include Express Inc (EXPRQ). Option delistings effective April 23rd include PGT Innovations Inc (PGTI), NGM Biopharmaceuticals Inc (NGM), Karuna Therapeutics Inc (KRTX), KINNATE BIOPHARMA INC (KNTE), Daseke Inc (DSKE), Tritium Dcfc Ltd (DCFC), Xtrackers MSCI All China Equity ETF (CN), CymaBay Therapeutics Inc (CBAY), Alteryx Inc (AYX), XTRACKERS MSCI CHINA A INCLUSION EQUITY ETF (ASHX), Recro Pharma, Inc. (SCTL), Splunk Inc (SPLK), and Textainer Group Holdings Limited (TGH).
